Jiangsu Hansoh Pharmaceutical Co., Ltd.
Clinical trials sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd., explained in plain language.
-
New hope for lung cancer: Fourth-Generation drug targets resistant mutations
Disease control Recruiting nowThis early-stage study tests a new oral drug, HS-10504, in people with advanced non-small cell lung cancer that has stopped responding to other EGFR-targeted treatments. The drug aims to block a specific cancer-driving mutation (C797S). Researchers will check safety, side effects…
Phase: PHASE1 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
New hope for PNH patients: experimental drug HS-10542 enters human trials
Disease control Recruiting nowThis study tests a new drug called HS-10542 in adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The goal is to see if the drug can safely raise hemoglobin levels and reduce the need for blood transfusions. About 50 partic…
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC